C
0.630
0.04 (6.78%)
| Penutupan Terdahulu | 0.590 |
| Buka | 0.600 |
| Jumlah Dagangan | 226,751 |
| Purata Dagangan (3B) | 38,332 |
| Modal Pasaran | 34,869,996 |
| Harga / Pendapatan (P/E Ke hadapan) | 0.770 |
| Harga / Jualan (P/S) | 1.25 |
| Harga / Buku (P/B) | 0.350 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 31 Mar 2025 |
| Margin Keuntungan | -88.66% |
| Margin Operasi (TTM) | 24.64% |
| EPS Cair (TTM) | -0.390 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.29% |
| Nisbah Semasa (MRQ) | 12.04 |
| Aliran Tunai Operasi (OCF TTM) | -24.75 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -17.08 M |
| Pulangan Atas Aset (ROA TTM) | -12.13% |
| Pulangan Atas Ekuiti (ROE TTM) | -17.92% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Connect Biopharma Holdings Limi | Bercampur | Bercampur |
AISkor Stockmoo
0.1
| Konsensus Penganalisis | 2.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | 0.13 |
|
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 41.16% |
| % Dimiliki oleh Institusi | 44.85% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Choreo, Llc | 31 Dec 2024 | 160,867 |
| Callan Capital, Llc | 31 Dec 2024 | 80,000 |
| Geowealth Management, Llc | 31 Dec 2024 | 10,942 |
| Julat 52 Minggu | ||
| Median | 8.00 (1,169.84%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 01 Apr 2025 | 8.00 (1,169.84%) | Beli | 0.572 |
| 31 Mar 2025 | 8.00 (1,169.84%) | Beli | 0.550 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 01 Apr 2025 | Pengumuman | Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart |
| 31 Mar 2025 | Pengumuman | Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update |
| 31 Mar 2025 | Pengumuman | Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma |
| 28 Mar 2025 | Pengumuman | Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement |
| 03 Mar 2025 | Pengumuman | Connect Biopharma to Present at Two Upcoming Investor Conferences |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |